Annual report pursuant to Section 13 and 15(d)

INTANGIBLE ASSETS

v3.22.1
INTANGIBLE ASSETS
 12 Months Ended
Dec. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]  
INTANGIBLE ASSETS

NOTE 5 – INTANGIBLE ASSETS

 

Intangible assets consisted of the following as of:

 

    Estimated life   December 31, 2021     December 31, 2020  
Trademarks   3 years   $ -     $ 22,060  
Website   3 years     10,799       10,799  
Accumulated amortization         (5,099 )     (10,954 )
        $ 5,700     $ 21,905  

 

As of December 31, 2021, estimated future amortization expenses related to intangible assets were as follows:

 

    Intangible Assets  
2022   $ 3,600  
2023     2,100  
Total   $ 5,700  

 

The Company had amortization expense of $16,205 and $10,954 for the years ended December 31, 2021 and 2020, respectively.

 

On January 8, 2020, James Joyce, the Company’s CEO and Craig Roberts, the Company’s COO, assigned to the Company the rights to patent 62/881,740 pertaining to the devices, systems and methods for the broad-spectrum reduction of pro-inflammatory cytokines in blood.